<DOC>
	<DOCNO>NCT01295645</DOCNO>
	<brief_summary>The goal clinical research study learn add cidofovir standard care improve symptom hemorrhagic cystitis cause BK virus compare standard care alone . The safety cidofovir also study .</brief_summary>
	<brief_title>Cidofovir Versus Best Supportive Care Hemorrhagic Cystitis</brief_title>
	<detailed_description>The Study Drug : Cidofovir anti-viral drug design treat prevent infection cause certain kind virus . Study Groups : If find eligible take part study , randomly assign ( flip coin ) 1 2 study group equal chance either group : - If Group 1 , receive standard care drug cidofovir . The doctor tell standard care drug take risk . - If Group 2 , receive standard care drug . Study Drug Administration : If Group 1 , receive cidofovir vein 1 hour 3 time per week . You also receive standard care , may include oral pain drug take every 4 6 hour need , oral drug urinary urgency take 2 time daily , fluid give vein increase urination rate . If Group 2 , receive standard care , describe . Study Visits : Each week : - Blood ( 2 tablespoon ) draw routine test . - You physical exam , include measurement vital sign . Every 2 week , complete questionnaire urinary problem . Length Study : If Group 1 , may continue take study drug 4 week . Group 2 take standard care 4 week . If doctor think need Groups 1 2 continue receive standard care study . If symptom get bad study receive cidofovir , may eligible treatment , may include cidofovir , study end . You longer able take study drug disease get bad intolerable side effect occur . Your participation study complete end-of-treatment visit follow-up visit . End-of-Treatment Visit : After finish treatment : - Urine collect test level BK virus . - You complete questionnaire urinary problem . Follow-up Visit : Four ( 4 ) week treatment end : - You physical exam , include measurement vital sign . - Urine collect test level BK virus . This investigational study . Cidofovir FDA approve commercially available treatment several viral infection . Its use patient BK virus stem cell transplant investigational . Up 40 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>1 . HSCT patient symptomatic hemorrhagic cystitis ( minimal Grade 1 symptom HC per NCI criterion ) positive BKV urine &gt; 1x103 DNA copies/ml 2 . Age &gt; /= 6 year 3 . Patient must sign informed consent document . 1 . Creatine clearance &lt; 55 ml/min , calculate use ideal body weight ( IBW ) use CockcroftGault equation 2 . Concomitant use foscarnet , liposomal amphotericin B aminoglycoside 3 . Use cidofovir bladder instillation 4 . Use formalin hyperbaric oxygen treatment</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Hemorrhagic Cystitis</keyword>
	<keyword>Bladder inflammation</keyword>
	<keyword>Frequent urination</keyword>
	<keyword>Pain</keyword>
	<keyword>Polyomavirus hominis type I</keyword>
	<keyword>BK virus</keyword>
	<keyword>BKV</keyword>
	<keyword>Cidofovir</keyword>
	<keyword>Vistide</keyword>
</DOC>